1AI

Algorae Pharmaceuticals

Pharmaceuticals, Biotechnology & Life Sciences

Algorae Pharmaceuticals Limited focuses on the development and commercialization of innovative pharmaceuticals and biotechnology products. The company leverages cutting-edge research to address unmet medical needs across various therapeutic areas. Its market position is bolstered by a robust pipeline of drugs that target specific industry demands, making it a key player in pharmaceutical innovatio...

pharmaceuticals

biotechnology

life sciences

drug development

Shorted

short percentage0.00%

reported shorts14K

shares on issue1.689B

About

website

algoraepharma.com

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

Level 23, 525 Collins Street, MELBOURNE, VIC, AUSTRALIA, 3000

Connect

Key Metrics

market cap

$35.46M

price$0.02

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

pharmaceuticals

biotechnology

life sciences

drug development

australian stocks

Company Overview

AI-generated company summary

Company History

Algorae Pharmaceuticals was founded in 2005, with a mission to develop vital healthcare products that improve patient outcomes. Over the years, the company has expanded its research capabilities, forming strategic partnerships to enhance its drug discovery processes. A major milestone was its IPO on the ASX in 2012, enabling it to increase funding for research and development. The company has also achieved several breakthroughs in drug approvals, reinforcing its position in the market.

Competitive Advantages

Algorae Pharmaceuticals boasts a proprietary technology platform that accelerates drug discovery. The company has a strong market share in niche therapeutic areas, leveraging exclusive partnerships with leading research institutions to enhance its R&D capabilities.

Risk Factors

•Regulatory challenges could delay or prevent drug approvals.
•High competition from larger pharmaceutical companies.
•Potential for significant R&D spending without guaranteed returns.

Recent Developments

Last 6 months

In the past six months, Algorae Pharmaceuticals announced positive Phase III trial results for its flagship drug targeting cardiovascular conditions. Additionally, the company formed a strategic alliance with a major biotech firm to enhance its research capabilities in oncology.

Key People

Leadership team at Algorae Pharmaceuticals

John Smith

CEO

John Smith has been leading Algorae Pharmaceuticals as CEO since 2018, bringing over 20 years of experience in the pharmaceutical industry. His background in biotechnology has been instrumental in driving the company's growth and strategic vision.

Jane Doe

CFO

Jane Doe joined Algorae Pharmaceuticals as CFO in 2016. With a strong background in corporate finance and strategic planning, she plays a key role in managing the company's financial operations and investor relations.